Portage Biotech (NASDAQ:PRTG) issued its quarterly earnings data on Tuesday. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.03, MarketWatch Earnings reports.
NASDAQ:PRTG opened at $16.99 on Wednesday. Portage Biotech has a 12 month low of $11.85 and a 12 month high of $44.98. The company’s 50 day moving average is $20.55 and its 200-day moving average is $22.42.
Several institutional investors have recently made changes to their positions in PRTG. Morgan Stanley acquired a new stake in shares of Portage Biotech in the first quarter worth $225,000. Bank of America Corp DE acquired a new stake in shares of Portage Biotech in the second quarter worth $38,000. Millennium Management LLC acquired a new stake in shares of Portage Biotech in the second quarter worth $245,000. Geode Capital Management LLC grew its stake in shares of Portage Biotech by 30.2% in the third quarter. Geode Capital Management LLC now owns 45,629 shares of the company’s stock worth $927,000 after acquiring an additional 10,590 shares during the last quarter. Finally, American International Group Inc. grew its stake in shares of Portage Biotech by 35.4% in the third quarter. American International Group Inc. now owns 2,736 shares of the company’s stock worth $56,000 after acquiring an additional 716 shares during the last quarter. Institutional investors and hedge funds own 7.10% of the company’s stock.
Portage Biotech Company Profile
Portage Biotech Inc, together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury.
Further Reading: What are momentum indicators and what do they show?
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.